Post by SOPHiA GENETICS

We are proud to announce a strategic collaboration with MD Anderson Cancer Center to accelerate the future of AI-driven precision oncology. By uniting SOPHiA GENETICS’ AI-powered analytics with MD Anderson’s world-renowned clinical and scientific expertise, we aim to accelerate data-driven cancer care through new tools that can accurately analyze, interpret and translate diagnostic results into clinical practice. Together, we are launching a series of R&D programs, including the co-development of an advanced NGS oncology test. Built on the advanced AI algorithms of the SOPHiA DDM™ Platform, the new co-developed test aims to translate complex multimodal data into actionable insights with greater speed and scale. Donna Hansel, M.D., Ph.D., Division Head of Pathology and Laboratory Medicine at MD Anderson, said: “Cancer research has evolved rapidly, and we have more health data available than ever before. Our collaboration with SOPHiA GENETICS reflects how our lab is evolving and integrating advanced analytics and AI to better interpret complex molecular information. This collaboration will expand our ability to translate high-dimensional data into insights that can meaningfully advance research and precision oncology.” Philippe Menu, M.D., Ph.D., Chief Product Officer and Chief Medical Officer, SOPHiA GENETICS, said: “This collaboration with MD Anderson amplifies our shared ambition to push the boundaries of what is possible in cancer research. With SOPHiA DDM™ as a unifying analytical layer, we are enabling new discoveries, accelerating breakthroughs in precision oncology and, most importantly, enabling patients around the globe to benefit from these innovations by bringing leading technologies to all geographies quickly and at scale.” Read the full announcement: https://loom.ly/RHk-t4Q

Video Content